Transaction details
On February 4, 2026, Jessie Hanrahan, who serves as Chief Regulatory Officer of Solid Biosciences Inc (NASDAQ: SLDB), sold 12,348 shares of common stock for a total of $79,544. The shares were disposed of at a weighted average price of $6.4419 per share, with the individual sales prices spanning from $6.28 to $6.60, according to the company filing.
Ownership and reason for sale
Following the transaction, Hanrahan retains direct ownership of 70,327 shares of Solid Biosciences common stock. A footnote to the SEC filing indicates the disposition was made to satisfy withholding tax obligations arising from the vesting of restricted stock units.
Market context and valuation
Solid Biosciences shares have appreciated approximately 126% over the past year. InvestingPro data cited in the filing shows the stock trading slightly above its assessed Fair Value and places the company's market capitalization at about $508 million. Market metrics underline a history of elevated share-price movement: SLDB carries a five-year beta of 2.65, a measure that signals higher-than-average volatility relative to the market.
Upcoming corporate timetable and external analysis
The company is scheduled to report earnings on March 6. InvestingPro's research flags several themes for Solid Biosciences, notably concerns over cash burn and pronounced price volatility; comprehensive coverage is available in the Pro Research Report referenced by the data provider.
Clinical and regulatory developments
In parallel with the reported insider transaction, Solid Biosciences continues to advance its clinical and regulatory programs. The company has dosed 33 participants in the Phase 1/2 INSPIRE DUCHENNE trial and reports that the investigational SGT-003 therapy has been generally well tolerated, with no significant adverse effects observed. Separately, the U.S. Food and Drug Administration granted Orphan Drug designation to Solid's investigational gene therapy SGT-212, which targets Friedreich's ataxia. That designation coincided with dosing of the first participant in the Phase 1b FALCON trial, a study employing a dual-route administration approach.
Solid Biosciences also commented on a broader screening development: the inclusion of Duchenne muscular dystrophy in the Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services, a change the company says should improve early detection and access to treatment.
Analyst stance
Citizens has reiterated a Market Outperform rating for Solid Biosciences, highlighting the company's proprietary capsid and unique dystrophin as advantages in its therapeutic approach.
This report compiles transaction details and company developments disclosed in regulatory filings and research notes. It is intended to present the facts reported in those documents without additional inference.